Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals

 Eli Lilly and Co. (LLY) said on Tuesday that in a phase III trial, its investigational monoclonal antibody Lebrikizumab considerably reduced the severity of moderate-to-severe atopic dermatitis, when combined with topical corticosteroids.